Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979615 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 129
- Enrollment target
NCT00979615 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 129 participants.
The verdict
NCT00979615, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 129 participants
- Enrollment target
Study Summary
The purpose of this study is to examine safety and efficacy of Patanase and Astelin in treating the symptoms of non-allergic vasomotor rhinitis (VMR).
Interventions
- DRUG Olopatadine HCL (Patanase) Nasal Spray, 0.6%
- DRUG Azelastine HCl (Astelin) Nasal Spray, 137 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00979615
The ClinicalTrials.gov registry entry for NCT00979615 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olopatadine HCL (Patanase) Nasal Spray, 0.6% is the first listed.
NCT00979615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00979615 about?
NCT00979615 is a clinical study titled "Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis". The purpose of this study is to examine safety and efficacy of Patanase and Astelin in treating the symptoms of non-allergic vasomotor rhinitis (VMR).
What is the current status of trial NCT00979615?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 129 participants. The study started on 2009-09.
What interventions are being tested in trial NCT00979615?
The interventions under investigation include: Olopatadine HCL (Patanase) Nasal Spray, 0.6% (DRUG), Azelastine HCl (Astelin) Nasal Spray, 137 mcg (DRUG).
Who is sponsoring clinical trial NCT00979615?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.